Progesterone acutely increases LH pulse amplitude but does not acutely influence nocturnal LH pulse frequency slowing during the late follicular phase in women.
Progesterone (P) is the primary effector of LH (and by inference gonadotropin-releasing hormone) pulse frequency slowing in cycling women, but the time course of this action is unclear. We hypothesized that P administration to estradiol (E2)-pretreated women would slow LH pulse frequency within 12 h. We studied eight normally cycling women in two separate cycles (follicular phase, cycle days 7-11). After 3 days of E2 pretreatment (0.2 mg/day via transdermal patches), a 25-h blood sampling protocol (starting at 0800) was performed to define LH pulsatility. Oral micronized P (100 mg) or placebo (PBO) was administered at 1800 in a randomized, double-blind fashion, with treatment crossover occurring during a subsequent cycle. The 10-h mean P concentration increased from 0.6+/-0.1 ng/ml before P (0800-1800) to 3.9+/-0.3 ng/ml after P administration (2200-0800, P<0.01). Ten-hour mean LH interpulse interval increased significantly after both P and PBO administration, with no significant difference between P and PBO. In contrast, mean LH, LH amplitude, and mean FSH increased significantly within 4 h of P administration, but not after PBO. We conclude that, in E2-pretreated women in the late follicular phase, 1) nocturnal LH pulse frequency is not acutely (within 12 h) influenced by P administration; 2) an acute increase in P causes pronounced augmentation of gonadotropin pulse amplitude within 4 h; and 3) LH pulse frequency slows overnight during the second half of the follicular phase.
McCartney
Christopher R
CR
Center for Research in Reproduction, Box 800391, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA. cm2hq@virginia.edu
Blank
Susan K
SK
Marshall
John C
JC
D000284:Administration, Oral; D000328:Adult; D002940:Circadian Rhythm / Q000187:drug effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000097:blood / Q000187:drug effects*; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D010919:Placebos; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D011673:Pulsatile Flow / Q000187:drug effects
D012739:Gonadal Steroid Hormones; D010919:Placebos; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone